Movement Alert｜CARsgen Biotech Falls 5.07% in Regular Trading, Fourth Straight Decline After Global First Solid Tumor CAR-T Approval

Market Focus06-26 11:45

On June 26, CARsgen Biotech (02171.HK) fell 5.07% in regular trading, trading at HKD 11.82/share, with turnover of HKD 63.15 million. This marks the fourth consecutive trading day of decline since the company announced its landmark drug approval on June 22, with cumulative losses exceeding 25%.

On June 22, CARsgen announced that its self-developed CAR-T product Satri-Cel (舒瑞基奥仑赛) received NMPA approval, becoming the world's first CAR-T therapy approved for solid tumors. The product is priced at RMB 990,000 per dose for treating advanced gastric/gastroesophageal junction adenocarcinoma. However, the high pricing has triggered significant market concerns over commercial viability. Management disclosed expectations of only 200 orders in the current year, with peak sales of approximately RMB 2 billion projected 4-5 years post-launch.

The broader biotech sector also traded under pressure, with AKESO down 4.97%, Remegen down 3.07%, and Innovent Bio down 2.3%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147278514?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 11:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147278514","market":"hk","top_or_hot":-1,"title":"Movement Alert｜CARsgen Biotech Falls 5.07% in Regular Trading, Fourth Straight Decline After Global First Solid Tumor CAR-T Approval","media":"Market Focus","content":"<p><p>On June 26, CARsgen Biotech (02171.HK) fell 5.07% in regular trading, trading at HKD 11.82/share, with turnover of HKD 63.15 million. This marks the fourth consecutive trading day of decline since the company announced its landmark drug approval on June 22, with cumulative losses exceeding 25%.</p><p>On June 22, CARsgen announced that its self-developed CAR-T product Satri-Cel (舒瑞基奥仑赛) received NMPA approval, becoming the world's first CAR-T therapy approved for solid tumors. The product is priced at RMB 990,000 per dose for treating advanced gastric/gastroesophageal junction adenocarcinoma. However, the high pricing has triggered significant market concerns over commercial viability. Management disclosed expectations of only 200 orders in the current year, with peak sales of approximately RMB 2 billion projected 4-5 years post-launch.</p><p>The broader biotech sector also traded under pressure, with AKESO down 4.97%, Remegen down 3.07%, and Innovent Bio down 2.3%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CARsgen Biotech Falls 5.07% in Regular Trading, Fourth Straight Decline After Global First Solid Tumor CAR-T Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CARsgen Biotech Falls 5.07% in Regular Trading, Fourth Straight Decline After Global First Solid Tumor CAR-T Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-26 11:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 26, CARsgen Biotech (02171.HK) fell 5.07% in regular trading, trading at HKD 11.82/share, with turnover of HKD 63.15 million. This marks the fourth consecutive trading day of decline since the company announced its landmark drug approval on June 22, with cumulative losses exceeding 25%.</p><p>On June 22, CARsgen announced that its self-developed CAR-T product Satri-Cel (舒瑞基奥仑赛) received NMPA approval, becoming the world's first CAR-T therapy approved for solid tumors. The product is priced at RMB 990,000 per dose for treating advanced gastric/gastroesophageal junction adenocarcinoma. However, the high pricing has triggered significant market concerns over commercial viability. Management disclosed expectations of only 200 orders in the current year, with peak sales of approximately RMB 2 billion projected 4-5 years post-launch.</p><p>The broader biotech sector also traded under pressure, with AKESO down 4.97%, Remegen down 3.07%, and Innovent Bio down 2.3%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科济药业-B","start_time":0,"source_url":"","article_id":"1147278514","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147278514","pubTimestamp":1782445522,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 26, CARsgen Biotech (02171.HK) fell 5.07% in regular trading, trading at HKD 11.82/share, with turnover of HKD 63.15 million. This marks the fourth consecutive trading day of decline since...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02171":"科济药业-B"},"translate_title":"动静快讯|科济生物常规交易跌5.07%全球首个实体瘤CAR-T获批后四连跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"On June 26, CARsgen Biotech (02171.HK) fell 5.07% in regular trading, trading at HKD 11.82/share, with turnover of HKD 63.15 million. This marks the fourth consecutive trading day of decline since the company announced its landmark drug approval on June 22, with cumulative losses exceeding 25%.On June 22, CARsgen announced that its self-developed CAR-T product Satri-Cel (舒瑞基奥仑赛) received NMPA approval, becoming the world's first CAR-T therapy approved for solid tumors. The product is priced at RMB 990,000 per dose for treating advanced gastric/gastroesophageal junction adenocarcinoma. However, the high pricing has triggered significant market concerns over commercial viability. Management disclosed expectations of only 200 orders in the current year, with peak sales of approximately RMB 2 billion projected 4-5 years post-launch.The broader biotech sector also traded under pressure, with AKESO down 4.97%, Remegen down 3.07%, and Innovent Bio down 2.3%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147278514","isCrawlerRequest":true}